International Journal of Clinical and Medical Research · مجلد 3 (1) · 47-50
Alzheimer Disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β deposition, tau pathology, synaptic dysfunction, neuronal injury and cerebral atrophy. Positron Emission Tomography (PET) has transformed AD evaluation by enabling in-vivo visualization of molecular and metabolic abnormalities. 18F-Fluorodeoxyglucose (FDG) PET evaluates cerebral glucose metabolism, amyloid PET identifies fibrillar amyloid-β and tau PET provides information about neurofibrillary pathology. This review examines diagnostic and prognostic applications of PET in AD, particularly in mild cognitive impairment, atypical dementia, differential diagnosis, disease staging, progression prediction and treatment selection. Evidence indicates that amyloid PET is highly useful for establishing amyloid pathology, whereas tau PET is more closely associated with disease stage and clinical severity. FDG PET remains valuable for identifying patterns of neurodegeneration and distinguishing AD from other dementias. With the emergence of disease-modifying anti-amyloid therapies, molecular confirmation has become increasingly relevant to treatment decisions. Important limitations include cost, availability, radiation exposure, tracer-specific limitations, mixed pathology and interpretation variability. Future integration of PET with MRI, blood biomarkers and artificial intelligence may improve individualized diagnosis, prognosis and therapeutic monitoring.
Alzheimer's diseasepositron emission tomographyamyloid PETtau PET
Frailty is one of the independent predictors of disability. There is a large shift in the Kingdom of Saudi Arabia toward improving health care system due to the increasing older adult population. Limited research has explained the relationship between frailty status and disability in Saudi older adults. Therefore, the aim of the current study was to investigate the relationship between physical frailty and disability using a cross-sectional design study. A total of 324 participants aged 50 years or older were recruited in the study; participants diagnosed with dementia, Alzheimer’s, or severe cognitive or physical impairment were excluded from the study. All participants underwent a physical examination procedure and completed structured questionnaires. Frailty status was determined using the FRAIL scale. Disability was categorized using the Activities of Daily Living scale. Samples were categorized based on frailty status (Frail, Pre-frail, and No-Frail) using the FRAIL scale. The sample’s mean age was 65.7 years, with females (71.7%) having a higher prevalence of disability than males (28.4%). Participants with two or more chronic conditions had a higher prevalence of disability (62.4%). The fully adjusted model shows that pre-frail (OR: 2.62; 95% CI [1.44, 4.97], p = 0.002) and frail (OR: 4.05; 95% CI [1.69, 9.65], p = 0.002) groups were significantly associated with having disability compared to robust group after adjustments for age, sex, BMI, and number of chronic conditions. This study provided a foundation for disability projects in Saudi Arabia to promote the understanding of the underlying mechanisms of the relationship between frailty and disability for the Saudi community.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. Public knowledge and awareness of AD play an important role in early recognition, risk reduction, and support for affected individuals. This study aimed to assess AD-related knowledge among adults in Riyadh, Saudi Arabia, using the validated Alzheimer’s Disease Knowledge Scale (ADKS), and to identify sociodemographic factors associated with knowledge levels. A community-based cross-sectional study was conducted among 1282 adults recruited from public locations across Riyadh using a stratified convenience sampling approach. Data were collected through face-to-face interviews using a structured questionnaire and the 30-item ADKS. The scale assessed knowledge across seven domains: life impact, risk factors, disease course, assessment and diagnosis, caregiving, treatment and management, and symptoms. Descriptive statistics, independent-samples t -tests, one-way analysis of variance, Tukey’s post hoc analysis, and multiple linear regression were performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). The mean total ADKS score was 17.09 ± 3.00 out of 30, corresponding to 56.95% correct responses, indicating moderate knowledge of AD among participants. The highest domain-specific knowledge scores were observed in assessment and diagnosis (66.25%) and treatment and management (66.25%), while the lowest scores were observed in caregiving (46.2%). Mean ADKS scores differed significantly by age group ( P = 0.037), gender ( P < 0.001), educational level ( P = 0.007), marital status ( P = 0.007), and family history of AD ( P < 0.001). Multiple linear regression analysis showed that female gender ( B = 0.952, P < 0.001), higher educational level ( B = 0.177, P = 0.012), increasing age category ( B = 0.229, P = 0.012), and having a family history of AD ( B = 0.800, P < 0.001) were independently associated with higher ADKS scores. Adults in Riyadh demonstrated moderate knowledge regarding AD, with notable knowledge gaps particularly related to caregiving and other disease-related domains. Sociodemographic characteristics, especially gender, education, age, and family exposure to AD, were associated with knowledge levels. Targeted community-based educational interventions addressing identified knowledge gaps are warranted to improve AD awareness and promote early recognition and supportive care in Saudi Arabia.
Pollution is ubiquitous, and much of it is anthropogenic in nature, which is a severe risk factor not only for respiratory infections or asthma sufferers but also for Alzheimer's disease, which has received a lot of attention recently. This Review aims to investigate the primary environmental risk factors and their profound impact on Alzheimer's disease. It underscores the pivotal role of multidimensional imaging in early disease identification and prevention. Conducting a comprehensive review, we delved into a plethora of literature sources available through esteemed databases, including Science Direct, Google Scholar, Scopus, Cochrane, and PubMed. Our search strategy incorporated keywords such as "Alzheimer Disease", "Alzheimer's", "Dementia", "Oxidative Stress", and "Phytotherapy" in conjunction with "Criteria Pollutants", "Imaging", "Pathology", and "Particulate Matter". Alzheimer's disease is not only a result of complex biological factors but is exacerbated by the infiltration of airborne particles and gases that surreptitiously breach the nasal defenses to traverse the brain, akin to a Trojan horse. Various imaging modalities and noninvasive techniques have been harnessed to identify disease progression in its incipient stages. However, each imaging approach possesses inherent limitations, prompting exploration of a unified technique under a single umbrella. Multidimensional imaging stands as the linchpin for detecting and forestalling the relentless march of Alzheimer's disease. Given the intricate etiology of the condition, identifying a prospective candidate for Alzheimer's disease may take decades, rendering the development of a multimodal imaging technique an imperative. This research underscores the pressing need to recognize the chronic ramifications of invisible particulate matter and to advance our understanding of the insidious environmental factors that contribute to Alzheimer's disease.
BACKGROUND: The Mediterranean diet has been linked to brain neuroprotection. Evidence from meta-analyses showed reduced risk of dementia with greater intake of vegetables and fruits, fish, and the Mediterranean diet. The current study raises important questions about the association between low risk dementia and Mediterranean diet. OBJECTIVE: The objective was to evaluate the association between levels of adherence to the Mediterranean diet and dementia and cognitive status in subjects 50 years of age and older. METHOD: The Mediterranean Diet Adherence Screener (MEDAS), the modified 30-item 'Diagnostic and Statistical Manual of Mental Disorders Third Edition (DSM-III) risk of dementia, and the Standard Mini-Mental Status Examination (SMMSE) cognitive status scores were used to assess the levels of adherence to the Mediterranean diet'. RESULTS: A total of 150 subjects were enrolled in the study. Forty-one (27.3%) had 'suspected or confirmed dementia, while 48 individuals (32%) were categorized as having moderate to severe cognitive decline. Subjects who reported moderate to high adherence to the Mediterranean diet (55, 36.7%) had significantly lower dementia scores (7.0 3.8 versus 17.6 5.1) and higher cognitive (25.4 3.8 versus 8.6 7.2) scores compared to those (38, 25.3%) who reported low adherence to the Mediterranean diet. CONCLUSION: Subjects who were highly or moderately adherent to the Mediterranean diet had significantly lower dementia scores and better cognitive status than those with low adherence.
Mediterranean dietdietary adherencedementiacognitive function
Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive, and incurable neurodegenerative disorder caused by prions. It is invariably fatal and classified under transmissible spongiform encephalopathies. This case report presents a 66-year-old Saudi female who was admitted to the neurology department due to a rapidly advancing cognitive decline. The patient underwent diagnostic evaluation, including magnetic resonance imaging (MRI) and electroencephalogram (EEG). Following a month of hospitalization with psychosocial support, the patient was stable and subsequently discharged. In conclusion, while CJD is an uncommon condition, it should be considered in the differential diagnosis of patients presenting with rapidly progressive dementia. Early and accurate diagnosis is essential to differentiate this untreatable disease from other treatable forms of rapidly progressive dementia and to facilitate potential future therapeutic interventions.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with unmet medical need, and is the leading cause of age-related dementia affecting millions of people worldwide. This work aims at developing small, high-drug loading capacity (DL) and -entrapment efficiency (EE) memantine hydrochloride (MEM)/chitosan nanocrystals (CS-NCs) to treat moderate to severe dementia associated with AD. MEM-loaded chitosan nanocrystals (MEM/CS-NCs, further abbreviated as MEM-NCs) were prepared by the ionic gelation method. Different formulations were prepared by varying the concentrations of CS and sodium tripolyphosphate (STPP). The prepared MEM-NCs formulations (n = 8) were evaluated for their particle size (PS), polydispersibility index (PDI), zeta potential (ZP), DL, EE and characterized by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Furthermore, in vitro (i.e., release behavior, cytotoxicity) and ex vivo studies (i.e., histopathology) studies were carried out. The results show that the DL was over 92% and the EE was higher than 73%, while the particles were relatively small with nanometric PS (152.63 ± 12.95 to 310.23 ± 10.49 nm), uniform with acceptable PDI (0.336 ± 0.05 to 0.534 ± 0.02), and stable with positive ZP (23.8 ± 0.4 mV to 54.0 ± 0.5 mV). The optimal formulation (MEM-NC3) was selected mainly based on the PS (152.63 ± 12.95 nm), DL (98.44 ± 3.31%), and EE (78.7 ± 3.11%). Interestingly, it does not elicit any cytotoxic and tissue damage when examining at goat nasal mucosa. The selected formulation was subjected to surface morphological studies such as transmission electron microscopy (TEM), which revealed that the NCs were spherical in shape and small (100 nm). Interestingly, the selected formulation was able to sustain the drug release for up to 24 h with an initial burst release (86.51 %). We conclude that the prepared MEM-NCs represent a promising drug formulation for further in vivo studies (in animal models and in a clinical setting) to prevent and treat AD.
Dementia-a syndrome affecting human cognition-is a major public health concern given to its rising prevalence worldwide. Though multiple research studies have analyzed disorders such as Alzheimer's disease and Frontotemporal dementia using a systems biology approach, a similar approach to dementia syndrome as a whole is required. In this study, we try to find the high-impact core regulating processes and factors involved in dementia's protein-protein interaction network. We also explore various aspects related to its stability and signal propagation. Using gene interaction databases such as STRING and GeneMANIA, a principal dementia network (PDN) consisting of 881 genes and 59,085 interactions was achieved. It was assortative in nature with hierarchical, scale-free topology enriched in various gene ontology (GO) categories and KEGG pathways, such as negative and positive regulation of apoptotic processes, macroautophagy, aging, response to drug, protein binding, etc. Using a clustering algorithm (Louvain method of modularity maximization) iteratively, we found a number of communities at different levels of hierarchy in PDN consisting of 95 "motif-localized hubs", out of which, 7 were present at deepest level and hence were key regulators (KRs) of PDN (HSP90AA1, HSP90AB1, EGFR, FYN, JUN, CELF2 and CTNNA3). In order to explore aspects of network's resilience, a knockout (of motif-localized hubs) experiment was carried out. It changed the network's topology from a hierarchal scale-free topology to scale-free, where independent clusters exhibited greater control. Additionally, network experiments on interaction of druggable genome and motif-localized hubs were carried out where UBC, EGFR, APP, CTNNB1, NTRK1, FN1, HSP90AA1, MDM2, VCP, CTNNA1 and GRB2 were identified as hubs in the resultant network (RN). We finally concluded that stability and resilience of PDN highly relies on motif-localized hubs (especially those present at deeper levels), making them important therapeutic intervention candidates. HSP90AA1, involved in heat shock response (and its master regulator, i.e., HSF1), and EGFR are most important genes in pathology of dementia apart from KRs, given their presence as KRs as well as hubs in RN.
Current Medicinal Chemistry · مجلد 30 (18) · 2061-2074
More than 10 million people worldwide have Alzheimer's disease (AD), a degenerative neurological illness and the most prevalent form of dementia. AD's progression in memory loss, cognitive deterioration, and behavioral changes are all symptoms. Amyloid-beta 42 (Aβ42), the hyperphosphorylated forms of microtubule-associated tau protein, and other cellular and systemic alterations are all factors that contribute to cognitive decline in AD. Rather than delivering a possible cure, present therapy strategies focus on reducing disease symptoms. It has long been suggested that various naturally occurring small molecules (plant extract products and microbiological isolates, for example) could be beneficial in preventing or treating disease. Small compounds, such as flavonoids, have attracted much interest recently due to their potential to alleviate cellular stress. Flavonoids have been proven helpful in various ways, including antioxidants, anti-inflammatory agents, and anti-apoptotic agents, but their mechanism remains unknown. The flavonoid therapy of Alzheimer's disease focuses on this review, which includes a comprehensive literature analysis.
Ageing process is accompanied by disrupted maintenance of tissue homeostasis. Declined cognitive function is a hallmark of ageing process. Patients with severe dementia and elderly people at an early stage of Alzheimer's disease demonstrated marked reduction in serum concentration of vitamin K. Menaquinone‐7 (MK‐7) is a major form of vitamin K2 that can be found in animal products and fermented food. The present study aimed to evaluate the potential protective effect of MK‐7 against cognitive decline and structural alterations in brain tissue of naturally aged rats and to delineate the potential involved molecular mechanisms. Three months‐aged albino rats were randomly assigned into two groups; ageing control receiving vehicle and ageing group received MK‐7 (30 mg/kg, oral, once daily 5 days per week). Treatment was continued for 17 months. Additional group containing three‐month‐old rats was used as adult control. Modified T‐maze, Crawley's sociability test and modified forced swim test were used to assess cognitive level, anxious and depressive like behaviour, respectively. Dissected brain tissues were used to assess neuroprotective mechanisms of MK‐7 by histopathology and immunohistochemistry, real time polymerase chain reaction, spectrophotometry and Enzyme‐Linked Immunosorbent assay. Behavioural tests showed attenuated cognitive impairment, depression and anxiety and improved spatial memory and learning ability by MK‐7 administration. Additionally, brain expression of NLRP3 inflammasome components (NLRP3, caspase‐1) and production of downstream inflammatory factors (IL‐1β, IL‐6 and TNF‐α) were markedly decreased in MK‐7 treated rats. Further, MK‐7 triggered Nrf‐2 expression, reduced lipid peroxidation and restored antioxidant enzymes levels. Also, MK‐7 dampened microglial activation, modulated hippocampal and cerebral cortical structure alterations and restored tyrosine expression in aged brain. Our findings highlighted MK‐7 as a promising candidate for halting progression of structural and cognitive deterioration in aged population. Activation of Nrf‐2 accompanied by NLRP3/ caspase‐1 suppression participated in neuroprotective effect of MK‐7 in rat aged brain.
Autism spectrum disorder (ASD) and Alzheimer's disease (AD) are neurodevelopmental and neurodegenerative disorders affecting two opposite ends of life span, i.e., childhood and old age. Both disorders pose a cumulative threat to human health, with the rate of incidences increasing considerably worldwide. In the context of recent developments, we aimed to review correlated symptoms and genetics, and overlapping aspects in the mechanisms of the pathogenesis of ASD and AD. Dementia, insomnia, and weak neuromuscular interaction, as well as communicative and cognitive impairments, are shared symptoms. A number of genes and proteins linked with both disorders have been tabulated, including MECP2, ADNP, SCN2A, NLGN, SHANK, PTEN, RELN, and FMR1. Theories about the role of neuron development, processing, connectivity, and levels of neurotransmitters in both disorders have been discussed. Based on the recent literature, the roles of FMRP (Fragile X mental retardation protein), hnRNPC (heterogeneous ribonucleoprotein-C), IRP (Iron regulatory proteins), miRNAs (MicroRNAs), and α-, β0, and γ-secretases in the posttranscriptional regulation of cellular synthesis and processing of APP (amyloid-β precursor protein) have been elaborated to describe the parallel and overlapping routes and mechanisms of ASD and AD pathogenesis. However, the interactive role of genetic and environmental factors, oxidative and metal ion stress, mutations in the associated genes, and alterations in the related cellular pathways in the development of ASD and AD needs further investigation.